Pharsight

Mirapex Er patents expiration

MIRAPEX ER's oppositions filed in EPO
MIRAPEX ER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
Apr, 2028

(4 years from now)

US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form
Sep, 2029

(5 years from now)

Mirapex Er is owned by Boehringer Ingelheim.

Mirapex Er contains Pramipexole Dihydrochloride.

Mirapex Er has a total of 2 drug patents out of which 0 drug patents have expired.

Mirapex Er was authorised for market use on 19 February, 2010.

Mirapex Er is available in tablet, extended release;oral dosage forms.

Mirapex Er can be used as treatment of parkinson's disease.

The generics of Mirapex Er are possible to be released after 08 September, 2029.

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 February, 2010

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MIRAPEX ER before it's drug patent expiration?
More Information on Dosage

MIRAPEX ER family patents

Family Patents